请输入您要查询的百科知识：

　

词条 Munir Pirmohamed
释义

  1. Background

  2. Research

  3. Awards

  4. Professional memberships

  5. Funding

  6. Publications

  7. References

Professor Sir Munir Pirmohamed is a clinical pharmacologist, geneticist and the NHS Chair of Pharmacogenetics.

Background

Munir Pirmohamed studied Medicine at the University of Liverpool from 1980 to 1985,[1] Professor Pirmohamed then went on to study a PhD in Pharmacology in 1993, and began working as a Consultant Physician at the Royal Liverpool University Hospital in 1996.[2] Professor Pirmohamed gained the position of Personal Chair in Clinical Pharmacology at The University of Liverpool in 2001, and went on to become the NHS Chair of Pharmacogenetics in 2007. Professor Pirmohamed is a member of the Commission on Human Medicines and Chair of its Pharmacovigilance Expert Advisory Group, in addition to the role of Deputy Director for the MRC Centre for Drug Safety Sciences in Liverpool. Alongside these responsibilities Professor Pirmohamed also sits on the advisory board for precision medicine company Geneix.

Research

Pharmacogenetics and drug safety are the main areas of Professor Pirmohamed's research. With a particular focus on adverse drug reactions, their role in improving prescription choices and the development of genetic tests for personalised medicine.

Awards

Professor Pirmohamed has received the William Withering Medal from the Royal College of Physicians and the IPIT award for Public Service from the University of North Carolina in the US.[3]

Awarded a knighthood in Queen's birthday honors in June 2015 for services to Medicine.

Professional memberships

  • British Medical Association
  • British Pharmacological Society
  • Association of Physicians
  • Medical Council on Alcohol
  • Medical Research Society
  • Fellowship of Postgraduate Medicine

Funding

Professor Pirmohamed has been awarded funding from The UK Department of Health, NIHR, MRC, Wellcome Trust, Wolfson Foundation, and the EU FP7 programme funds

.[4]

Publications

  • Metabolism and bioactivation of clozapine by human liver in vitro[5]
  • Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis[6]
  • Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.[7]
  • Anticipating, investigating and managing the adverse effects of drugs[8]
  • TNF-alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients[9]
  • Are chemically reactive metabolites responsible for adverse reactions to drugs?[10]
  • TNF-alpha promoter region gene polymorphisms in HIV-positive subjects with lipodystrophy[11]
  • Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro[12]
  • Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes[13]
  • A method for the rapid depletion of albumin and immunoglobulin from human plasma[14]
  • Active Transport Of Imatinib Into And Out Of Cells: Implications For Drug Resistance[15]
  • Whole blood cultures from renal transplant patients stimulated ex-vivo show that the effects of cyclosporin on lymphocyte proliferation are related to P-glycoprotein expression[16]
  • Active transport of imatinib into and out of cells: implications for drug resistance[15]
  • Cost-effectiveness analysis of HLA B5701 genotyping in preventing abacavir hypersensitivity[17]
  • Whole blood cultures from renal transplant patients stimulated ex-vivo show that the effects of cyclosporin on lymphocyte proliferation are related to P-glycoprotein expression[16]
  • Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients[18]
  • The role of metabolic activation in drug-induced hepatotoxicity[19]
  • Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver[20]
  • Characterization of the T-cell response in a patient with phenindione hypersensitivity[21]
  • Carbamazepine-induced acute liver failure as part of the DRESS syndrome[22]
  • hOCT 1 and resistance to imatinib[23]
  • Drug presentation to T cells[24]
  • Characterization of the T-cell response in a patient with phenindione hypersensitivity[21]
  • Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors[25]
  • Investigation of toxic metabolites during drug development[26]
  • Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens[27]
  • How do NHS general hospitals in England deal with patients with alcohol-related problems? A questionnaire survey[28]
  • The quality of information on monitoring for haematological adverse drug reactions[29]
  • The pharmacogenetics of HIV therapy[30]
  • Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study[31]
  • Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements[32]
  • Clinical practice. Antibiotic allergy[33]
  • Pharmacogenetics in clinical practice: considerations for testing[34]
  • Beyond registration—measuring the public-health potential of new treatments for malaria in Africa[35]
  • Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan[36]
  • Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster[37]
  • Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling[38]
  • Warfarin: almost 60 years old and still causing problems[39]
  • Exon resequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance[40]
  • Activation of T-cells by carbamazepine and carbamazepine metabolites[41]
  • The future prospects of pharmacogenetics in oral anticoagulation therapy[42]
  • Genetic factors in the predisposition to drug-induced hypersensitivity reactions[43]
  • The HLA B locus in Caucasians patients with carbamazepine hypersensitivity[44]
  • Adverse drug reactions in hospital in-patients: A pilot study[45]
  • Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis[46]
  • Generation and characterization of antigen-specific CD4(+), CD8(+), and CD4(+)CD8(+) T-cell clones from patients with carbamazopine hypersensitivity[47]
  • Herbal medicines and acute medical emergency admissions to hospital[48]
  • Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity[49]
  • Immunological principles of T-cell-mediated adverse drug reactions in skin[50]
  • Folate Augmentation of Treatment - Evaluation for Depression (FolATED): protocol of a randomised controlled trial[51]
  • Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling[38]
  • Genetics of epilepsy: epilepsy research foundation workshop report[52]
  • Tacrine-induced liver damage: an analysis of 19 candidate genes[53]

References

1. ^{{cite web|title=Munir Pirmohamed|url=https://uk.linkedin.com/pub/munir-pirmohamed/23/30b/14a|website=LinkedIn|accessdate=4 March 2015}}
2. ^{{cite web|title=Professor Munir Pirmohamed|url=https://www.liv.ac.uk/north-west-england-mrc-fellowship-cpt/supervisors/munir-pirmohamed/|website=www.liv.ac.uk|accessdate=4 March 2015}}
3. ^{{cite web|title=Collaboration for Leadership in Applied Health Research and Care North West Coast|url=http://www.clahrc-nwc.nihr.ac.uk/about-us/our-team.php|website=www.clahrc-nwc.nihr.ac.uk|accessdate=4 March 2015}}
4. ^{{cite web|title=Munir PIRMOHAMED, Research and Innovation|url=http://ec.europa.eu/research/health/events-06-munir-pirmohamed_en.html|website=ec.europa.eu|accessdate=4 March 2015}}
5. ^{{cite journal|last1=Pirmohamed|first1=M|last2=Williams|first2=D|last3=Madden|first3=S|last4=Templeton|first4=E|last5=Park|first5=BK|title=Metabolism and bioactivation of clozapine by human liver in vitro.|journal=The Journal of Pharmacology and Experimental Therapeutics|date=March 1995|volume=272|issue=3|pages=984–90|pmid=7891353}}
6. ^{{cite journal|last1=Williams|first1=DP|last2=Pirmohamed|first2=M|last3=Naisbitt|first3=DJ|last4=Maggs|first4=JL|last5=Park|first5=BK|title=Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis.|journal=The Journal of Pharmacology and Experimental Therapeutics|date=December 1997|volume=283|issue=3|pages=1375–82|pmid=9400013}}
7. ^{{cite journal|last1=Williams|first1=DP|last2=Pirmohamed|first2=M|last3=Naisbitt|first3=DJ|last4=Uetrecht|first4=JP|last5=Park|first5=BK|title=Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine.|journal=Molecular Pharmacology|date=July 2000|volume=58|issue=1|pages=207–16|pmid=10860943}}
8. ^{{cite journal|last1=Pirmohamed|first1=M|title=Anticipating, investigating and managing the adverse effects of drugs.|journal=Clinical Medicine |volume=5|issue=1|pages=23–6|pmid=15745193|doi=10.7861/clinmedicine.5-1-23}}
9. ^{{cite journal|last1=Pirmohamed|first1=M|last2=Lin|first2=K|last3=Chadwick|first3=D|last4=Park|first4=BK|title=TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients.|journal=Neurology|date=10 April 2001|volume=56|issue=7|pages=890–6|pmid=11294926|doi=10.1212/wnl.56.7.890}}
10. ^{{cite journal|last1=Williams|first1=DP|last2=Kitteringham|first2=NR|last3=Naisbitt|first3=DJ|last4=Pirmohamed|first4=M|last5=Smith|first5=DA|last6=Park|first6=BK|title=Are chemically reactive metabolites responsible for adverse reactions to drugs?|journal=Current Drug Metabolism|date=August 2002|volume=3|issue=4|pages=351–66|pmid=12093355|doi=10.2174/1389200023337423}}
11. ^{{cite journal|last1=Maher|first1=B|last2=Alfirevic|first2=A|last3=Vilar|first3=FJ|last4=Wilkins|first4=EG|last5=Park|first5=BK|last6=Pirmohamed|first6=M|title=TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy.|journal=AIDS |date=18 October 2002|volume=16|issue=15|pages=2013–8|pmid=12370499|doi=10.1097/00002030-200210180-00005}}
12. ^{{cite journal|last1=Williams|first1=DP|last2=O'Donnell|first2=CJ|last3=Maggs|first3=JL|last4=Leeder|first4=JS|last5=Uetrecht|first5=J|last6=Pirmohamed|first6=M|last7=Park|first7=BK|title=Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro.|journal=Chemical Research in Toxicology|date=October 2003|volume=16|issue=10|pages=1359–64|pmid=14565776|doi=10.1021/tx034035z}}
13. ^{{cite journal|last1=Janneh|first1=O|last2=Hoggard|first2=PG|last3=Tjia|first3=JF|last4=Jones|first4=SP|last5=Khoo|first5=SH|last6=Maher|first6=B|last7=Back|first7=DJ|last8=Pirmohamed|first8=M|title=Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes.|journal=Antiviral Therapy|date=October 2003|volume=8|issue=5|pages=417–26|pmid=14640389}}
14. ^{{cite journal|last1=Greenough|first1=C|last2=Jenkins|first2=RE|last3=Kitteringham|first3=NR|last4=Pirmohamed|first4=M|last5=Park|first5=BK|last6=Pennington|first6=SR|title=A method for the rapid depletion of albumin and immunoglobulin from human plasma.|journal=Proteomics|date=October 2004|volume=4|issue=10|pages=3107–11|pmid=15378708|doi=10.1002/pmic.200300815}}
15. ^1 {{cite journal|last1=Thomas|first1=J|last2=Wang|first2=L|last3=Clark|first3=RE|last4=Pirmohamed|first4=M|title=Active transport of imatinib into and out of cells: implications for drug resistance.|journal=Blood|date=1 December 2004|volume=104|issue=12|pages=3739–45|pmid=15315971|doi=10.1182/blood-2003-12-4276}}
16. ^1 {{cite journal|last1=Singh|first1=D|last2=Alexander|first2=J|last3=Owen|first3=A|last4=Rustom|first4=R|last5=Bone|first5=M|last6=Hammad|first6=A|last7=Roberts|first7=N|last8=Park|first8=K|last9=Pirmohamed|first9=M|title=Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression.|journal=Transplantation|date=27 February 2004|volume=77|issue=4|pages=557–61|pmid=15084935|doi=10.1097/01.tp.0000114594.21317.a5}}
17. ^{{cite journal|last1=Hughes|first1=DA|last2=Vilar|first2=FJ|last3=Ward|first3=CC|last4=Alfirevic|first4=A|last5=Park|first5=BK|last6=Pirmohamed|first6=M|title=Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.|journal=Pharmacogenetics|date=June 2004|volume=14|issue=6|pages=335–42|pmid=15247625|doi=10.1097/00008571-200406000-00002}}
18. ^{{cite journal|last1=Pirmohamed|first1=M|last2=James|first2=S|last3=Meakin|first3=S|last4=Green|first4=C|last5=Scott|first5=AK|last6=Walley|first6=TJ|last7=Farrar|first7=K|last8=Park|first8=BK|last9=Breckenridge|first9=AM|title=Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.|journal=BMJ |date=3 July 2004|volume=329|issue=7456|pages=15–9|pmid=15231615|doi=10.1136/bmj.329.7456.15|pmc=443443}}
19. ^{{cite journal|last1=Park|first1=BK|last2=Kitteringham|first2=NR|last3=Maggs|first3=JL|last4=Pirmohamed|first4=M|last5=Williams|first5=DP|title=The role of metabolic activation in drug-induced hepatotoxicity.|journal=Annual Review of Pharmacology and Toxicology|date=2005|volume=45|pages=177–202|pmid=15822174|doi=10.1146/annurev.pharmtox.45.120403.100058}}
20. ^{{cite journal|last1=Owen|first1=A|last2=Goldring|first2=C|last3=Morgan|first3=P|last4=Chadwick|first4=D|last5=Park|first5=BK|last6=Pirmohamed|first6=M|title=Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver.|journal=British Journal of Clinical Pharmacology|date=March 2005|volume=59|issue=3|pages=365–70|pmid=15752383|doi=10.1111/j.1365-2125.2005.02229.x|pmc=1884787}}
21. ^1 {{cite journal|last1=Naisbitt|first1=DJ|last2=Farrell|first2=J|last3=Chamberlain|first3=PJ|last4=Hopkins|first4=JE|last5=Berry|first5=NG|last6=Pirmohamed|first6=M|last7=Park|first7=BK|title=Characterization of the T-cell response in a patient with phenindione hypersensitivity.|journal=The Journal of Pharmacology and Experimental Therapeutics|date=June 2005|volume=313|issue=3|pages=1058–65|pmid=15743920|doi=10.1124/jpet.105.083758}}
22. ^{{cite journal|last1=Syn|first1=WK|last2=Naisbitt|first2=DJ|last3=Holt|first3=AP|last4=Pirmohamed|first4=M|last5=Mutimer|first5=DJ|title=Carbamazepine-induced acute liver failure as part of the DRESS syndrome.|journal=International Journal of Clinical Practice|date=August 2005|volume=59|issue=8|pages=988–91|pmid=16033627|doi=10.1111/j.1368-5031.2005.00550.x}}
23. ^{{cite journal|last1=Crossman|first1=LC|last2=Druker|first2=BJ|last3=Deininger|first3=MW|last4=Pirmohamed|first4=M|last5=Wang|first5=L|last6=Clark|first6=RE|title=hOCT 1 and resistance to imatinib.|journal=Blood|date=1 August 2005|volume=106|issue=3|pages=1133–4; author reply 1134|pmid=16033955|doi=10.1182/blood-2005-02-0694}}
24. ^{{cite journal|last1=Naisbitt|first1=DJ|last2=Pirmohamed|first2=M|last3=Park|first3=BK|title=Drug presentation to T cells.|journal=The Journal of Allergy and Clinical Immunology|date=April 2005|volume=115|issue=4|pages=876-7; author reply 877-8|pmid=15806015|doi=10.1016/j.jaci.2005.01.011}}
25. ^{{cite journal|last1=Jones|first1=SP|last2=Janneh|first2=O|last3=Back|first3=DJ|last4=Pirmohamed|first4=M|title=Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.|journal=Antiviral Therapy|date=2005|volume=10|issue=2|pages=207–13|pmid=15865214}}
26. ^{{cite journal|last1=Park|first1=K|last2=Williams|first2=DP|last3=Naisbitt|first3=DJ|last4=Kitteringham|first4=NR|last5=Pirmohamed|first5=M|title=Investigation of toxic metabolites during drug development.|journal=Toxicology and Applied Pharmacology|date=1 September 2005|volume=207|issue=2 Suppl|pages=425–34|pmid=15996699|doi=10.1016/j.taap.2005.02.029}}
27. ^{{cite journal|last1=Jones|first1=SP|last2=Qazi|first2=N|last3=Morelese|first3=J|last4=Lebrecht|first4=D|last5=Sutinen|first5=J|last6=Yki-Jărvinen|first6=H|last7=Back|first7=DJ|last8=Pirmohamed|first8=M|last9=Gazzard|first9=BG|last10=Walker|first10=UA|last11=Moyle|first11=GJ|title=Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.|journal=Journal of Acquired Immune Deficiency Syndromes |date=15 December 2005|volume=40|issue=5|pages=565–72|pmid=16284533|doi=10.1097/01.qai.0000187443.30838.3e}}
28. ^{{cite journal|last1=Owens|first1=L|last2=Gilmore|first2=IT|last3=Pirmohamed|first3=M|title=How do NHS general hospitals in England deal with patients with alcohol-related problems? A questionnaire survey.|journal=Alcohol and Alcoholism |volume=40|issue=5|pages=409–12|pmid=16009672|doi=10.1093/alcalc/agh184}}
29. ^{{cite journal|last1=Ferner|first1=RE|last2=Coleman|first2=J|last3=Pirmohamed|first3=M|last4=Constable|first4=SA|last5=Rouse|first5=A|title=The quality of information on monitoring for haematological adverse drug reactions.|journal=British Journal of Clinical Pharmacology|date=October 2005|volume=60|issue=4|pages=448–51|pmid=16187979|doi=10.1111/j.1365-2125.2005.02440.x|pmc=1884821}}
30. ^{{cite journal|last1=Owen|first1=A|last2=Pirmohamed|first2=M|last3=Khoo|first3=SH|last4=Back|first4=DJ|title=Pharmacogenetics of HIV therapy.|journal=Pharmacogenetics and Genomics|date=October 2006|volume=16|issue=10|pages=693–703|pmid=17001288|doi=10.1097/01.fpc.0000236338.41799.57}}
31. ^{{cite journal|last1=Leschziner|first1=G|last2=Jorgensen|first2=AL|last3=Andrew|first3=T|last4=Pirmohamed|first4=M|last5=Williamson|first5=PR|last6=Marson|first6=AG|last7=Coffey|first7=AJ|last8=Middleditch|first8=C|last9=Rogers|first9=J|last10=Bentley|first10=DR|last11=Chadwick|first11=DW|last12=Balding|first12=DJ|last13=Johnson|first13=MR|title=Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study.|journal=The Lancet. Neurology|date=August 2006|volume=5|issue=8|pages=668–76|pmid=16857572|doi=10.1016/s1474-4422(06)70500-2}}
32. ^{{cite journal|last1=Owen|first1=A|last2=Goldring|first2=C|last3=Morgan|first3=P|last4=Park|first4=BK|last5=Pirmohamed|first5=M|title=Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements.|journal=British Journal of Clinical Pharmacology|date=August 2006|volume=62|issue=2|pages=237–42|pmid=16842400|doi=10.1111/j.1365-2125.2006.02587.x|pmc=1885083}}
33. ^{{cite journal|last1=Gruchalla|first1=RS|last2=Pirmohamed|first2=M|title=Clinical practice. Antibiotic allergy.|journal=The New England Journal of Medicine|date=9 February 2006|volume=354|issue=6|pages=601–9|pmid=16467547|doi=10.1056/nejmcp043986}}
34. ^{{cite journal|last1=Constable|first1=S|last2=Johnson|first2=MR|last3=Pirmohamed|first3=M|title=Pharmacogenetics in clinical practice: considerations for testing.|journal=Expert Review of Molecular Diagnostics|date=March 2006|volume=6|issue=2|pages=193–205|pmid=16512779|doi=10.1586/14737159.6.2.193}}
35. ^{{cite journal|last1=Lang|first1=T|last2=Hughes|first2=D|last3=Kanyok|first3=T|last4=Kengeya-Kayondo|first4=J|last5=Marsh|first5=V|last6=Haaland|first6=A|last7=Pirmohamed|first7=M|last8=Winstanley|first8=P|title=Beyond registration--measuring the public-health potential of new treatments for malaria in Africa.|journal=The Lancet. Infectious Diseases|date=January 2006|volume=6|issue=1|pages=46–52|pmid=16377534|doi=10.1016/s1473-3099(05)70326-1}}
36. ^{{cite journal|last1=Constable|first1=S|last2=Farrell|first2=J|last3=Naisbitt|first3=D|last4=King|first4=C|last5=Leonard|first5=N|last6=Pirmohamed|first6=M|title=Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan.|journal=The British Journal of Dermatology|date=August 2006|volume=155|issue=2|pages=491–3|pmid=16882204|doi=10.1111/j.1365-2133.2006.07338.x}}
37. ^{{cite journal|last1=Alfirevic|first1=A|last2=Mills|first2=T|last3=Harrington|first3=P|last4=Pinel|first4=T|last5=Sherwood|first5=J|last6=Jawaid|first6=A|last7=Smith|first7=JC|last8=March|first8=RE|last9=Barratt|first9=BJ|last10=Chadwick|first10=DW|last11=Kevin Park|first11=B|last12=Pirmohamed|first12=M|title=Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster.|journal=Pharmacogenetics and Genomics|date=April 2006|volume=16|issue=4|pages=287–96|pmid=16538175|doi=10.1097/01.fpc.0000189800.88596.7a}}
38. ^1 {{cite journal|last1=Sanderson|first1=JP|last2=Naisbitt|first2=DJ|last3=Farrell|first3=J|last4=Ashby|first4=CA|last5=Tucker|first5=MJ|last6=Rieder|first6=MJ|last7=Pirmohamed|first7=M|last8=Clarke|first8=SE|last9=Park|first9=BK|title=Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling.|journal=Journal of Immunology |date=1 May 2007|volume=178|issue=9|pages=5533–42|pmid=17442935|doi=10.4049/jimmunol.178.9.5533}}
39. ^{{cite journal|last1=Pirmohamed|first1=M|title=Warfarin: almost 60 years old and still causing problems.|journal=British Journal of Clinical Pharmacology|date=November 2006|volume=62|issue=5|pages=509–11|pmid=17061959|doi=10.1111/j.1365-2125.2006.02806.x|pmc=1885167}}
40. ^{{cite journal|last1=Leschziner|first1=G|last2=Zabaneh|first2=D|last3=Pirmohamed|first3=M|last4=Owen|first4=A|last5=Rogers|first5=J|last6=Coffey|first6=AJ|last7=Balding|first7=DJ|last8=Bentley|first8=DB|last9=Johnson|first9=MR|title=Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance.|journal=Pharmacogenetics and Genomics|date=June 2006|volume=16|issue=6|pages=439–50|pmid=16708052|doi=10.1097/01.fpc.0000197467.21964.67}}
41. ^{{cite journal|last1=Wu|first1=Y|last2=Sanderson|first2=JP|last3=Farrell|first3=J|last4=Drummond|first4=NS|last5=Hanson|first5=A|last6=Bowkett|first6=E|last7=Berry|first7=N|last8=Stachulski|first8=AV|last9=Clarke|first9=SE|last10=Pichler|first10=WJ|last11=Pirmohamed|first11=M|last12=Park|first12=BK|last13=Naisbitt|first13=DJ|title=Activation of T cells by carbamazepine and carbamazepine metabolites.|journal=The Journal of Allergy and Clinical Immunology|date=July 2006|volume=118|issue=1|pages=233–41|pmid=16815161|doi=10.1016/j.jaci.2006.03.005}}
42. ^{{cite journal|last1=Kamali|first1=F|last2=Pirmohamed|first2=M|title=The future prospects of pharmacogenetics in oral anticoagulation therapy.|journal=British Journal of Clinical Pharmacology|date=June 2006|volume=61|issue=6|pages=746–51|pmid=16722840|doi=10.1111/j.1365-2125.2006.02679.x|pmc=1885126}}
43. ^{{cite journal|last1=Pirmohamed|first1=M|title=Genetic factors in the predisposition to drug-induced hypersensitivity reactions.|journal=The AAPS Journal|date=3 February 2006|volume=8|issue=1|pages=E20-6|pmid=16584129|doi=10.1208/aapsj080103|pmc=2751420}}
44. ^{{cite journal|last1=Alfirevic|first1=A|last2=Jorgensen|first2=AL|last3=Williamson|first3=PR|last4=Chadwick|first4=DW|last5=Park|first5=BK|last6=Pirmohamed|first6=M|title=HLA-B locus in Caucasian patients with carbamazepine hypersensitivity.|journal=Pharmacogenomics|date=September 2006|volume=7|issue=6|pages=813–8|pmid=16981842|doi=10.2217/14622416.7.6.813}}
45. ^{{cite journal|last1=Davies|first1=EC|last2=Green|first2=CF|last3=Mottram|first3=DR|last4=Pirmohamed|first4=M|title=Adverse drug reactions in hospital in-patients: a pilot study.|journal=Journal of Clinical Pharmacy and Therapeutics|date=August 2006|volume=31|issue=4|pages=335–41|pmid=16882102|doi=10.1111/j.1365-2710.2006.00744.x}}
46. ^{{cite journal|last1=Drummond|first1=NS|last2=Vilar|first2=FJ|last3=Naisbitt|first3=DJ|last4=Hanson|first4=A|last5=Woods|first5=A|last6=Park|first6=BK|last7=Pirmohamed|first7=M|title=Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis.|journal=Antiviral Therapy|date=2006|volume=11|issue=3|pages=393–5|pmid=16759058}}
47. ^{{cite journal|last1=Wu|first1=Y|last2=Farrell|first2=J|last3=Pirmohamed|first3=M|last4=Park|first4=BK|last5=Naisbitt|first5=DJ|title=Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity.|journal=The Journal of Allergy and Clinical Immunology|date=April 2007|volume=119|issue=4|pages=973–81|pmid=17320939|doi=10.1016/j.jaci.2006.12.617}}
48. ^{{cite journal|last1=Constable|first1=S|last2=Ham|first2=A|last3=Pirmohamed|first3=M|title=Herbal medicines and acute medical emergency admissions to hospital.|journal=British Journal of Clinical Pharmacology|date=February 2007|volume=63|issue=2|pages=247–8|pmid=17096679|doi=10.1111/j.1365-2125.2006.02817.x|pmc=2000573}}
49. ^{{cite journal|last1=Carr|first1=DF|last2=Alfirevic|first2=A|last3=Tugwood|first3=JD|last4=Barratt|first4=BJ|last5=Sherwood|first5=J|last6=Smith|first6=J|last7=Pirmohamed|first7=M|last8=Park|first8=BK|title=Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity.|journal=Pharmacogenetics and Genomics|date=November 2007|volume=17|issue=11|pages=961–72|pmid=18075466|doi=10.1097/fpc.0b013e3282f00919}}
50. ^{{cite journal|last1=Naisbitt|first1=DJ|last2=Pirmohamed|first2=M|last3=Park|first3=BK|title=Immunological principles of T-cell-mediated adverse drug reactions in skin.|journal=Expert Opinion on Drug Safety|date=March 2007|volume=6|issue=2|pages=109–24|pmid=17367257|doi=10.1517/14740338.6.2.109}}
51. ^{{cite journal|last1=Roberts|first1=SH|last2=Bedson|first2=E|last3=Hughes|first3=D|last4=Lloyd|first4=K|last5=Menkes|first5=DB|last6=Moat|first6=S|last7=Pirmohamed|first7=M|last8=Slegg|first8=G|last9=Thome|first9=J|last10=Tranter|first10=R|last11=Whitaker|first11=R|last12=Wilkinson|first12=C|last13=Russell|first13=I|title=Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial.|journal=BMC Psychiatry|date=15 November 2007|volume=7|pages=65|pmid=18005429|doi=10.1186/1471-244x-7-65|pmc=2238748}}
52. ^{{cite journal|last1=Sisodiya|first1=S|last2=Cross|first2=JH|last3=Blümcke|first3=I|last4=Chadwick|first4=D|last5=Craig|first5=J|last6=Crino|first6=PB|last7=Debenham|first7=P|last8=Delanty|first8=N|last9=Elmslie|first9=F|last10=Gardiner|first10=M|last11=Golden|first11=J|last12=Goldstein|first12=D|last13=Greenberg|first13=DA|last14=Guerrini|first14=R|last15=Hanna|first15=M|last16=Harris|first16=J|last17=Harrison|first17=P|last18=Johnson|first18=MR|last19=Kirov|first19=G|last20=Kullman|first20=DM|last21=Makoff|first21=A|last22=Marini|first22=C|last23=Nabbout|first23=R|last24=Nashef|first24=L|last25=Noebels|first25=JL|last26=Ottman|first26=R|last27=Pirmohamed|first27=M|last28=Pitkänen|first28=A|last29=Scheffer|first29=I|last30=Shorvon|first30=S|last31=Sills|first31=G|last32=Wood|first32=N|last33=Zuberi|first33=S|title=Genetics of epilepsy: epilepsy research foundation workshop report.|journal=Epileptic Disorders |date=June 2007|volume=9|issue=2|pages=194–236|pmid=17525034|doi=10.1684/epd.2007.0107}}
53. ^{{cite journal|last1=Alfirevic|first1=A|last2=Mills|first2=T|last3=Carr|first3=D|last4=Barratt|first4=BJ|last5=Jawaid|first5=A|last6=Sherwood|first6=J|last7=Smith|first7=JC|last8=Tugwood|first8=J|last9=Hartkoorn|first9=R|last10=Owen|first10=A|last11=Park|first11=KB|last12=Pirmohamed|first12=M|title=Tacrine-induced liver damage: an analysis of 19 candidate genes.|journal=Pharmacogenetics and Genomics|date=December 2007|volume=17|issue=12|pages=1091–100|pmid=18004213|doi=10.1097/fpc.0b013e3282f1f12b}}
{{authority control}}{{DEFAULTSORT:Pirmohamed, Munir}}

6 : Year of birth missing (living people)|Living people|Alumni of the University of Liverpool|British pharmacologists|Clinical pharmacologists|Knights Bachelor
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/17 10:14:14